Bio Preventive Medicine Corp. (BPM), a leading company in renal biomarker area, focuses on translating clinically validated and IP-protected (>79 patents) biomarkers into precision diagnostic solutions for unmet clinical needs. The disease area we focus on includes diabetic kidney disease (DKD), renal injury, and oncology.

Human uPTM3-DKD (DNlite-IVD013) ELISA test is a urinary prognosis test for predicting/monitoring risk of kidney disease progression, and is perfect for routine clinical practice in any healthcare institutes and clinical labs. Besides precision management of DKD, it can also be applied for risk assessment of Acute Kidney Disease, and Graft Failure in kidney transplant patients.

Commercially, DNlite-IVD103 is CE-IVD marked, approved by Malaysia MDA, and also launched in Japan and US as RUO kit. Furthermore, several other worldwide regulatory approvals are in preparation. BPM is ISO17025 and ISO13485 accredited, and listed in Taiwan emerging stock market (code: 6810).